Related Experiment Video
Updated: Nov 10, 2025
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Novel Molecular Hallmarks of Group 3 Medulloblastoma by Single-Cell Transcriptomics
Chaoying Qin1, Yimin Pan1, Yuzhe Li1
1Department of Neurosurgery in Xiangya Hospital, Central South University, Changsha, China.
Abstract:
Medulloblastoma (MB) is a highly heterogeneous and one of the most malignant pediatric brain tumors, comprising four subgroups: Sonic Hedgehog, Wingless, Group 3, and Group 4. Group 3 MB has the worst prognosis of all MBs. However, the molecular and cellular mechanisms driving the maintenance of malignancy are poorly understood. Here, we employed high-throughput single-cell and bulk RNA sequencing to identify novel molecular features of Group 3 MB, and found that a specific cell cluster displayed a highly malignant phenotype. Then, we identified the glutamate receptor metabotropic 8 (GRM8), and AP-1 complex subunit sigma-2 (AP1S2) genes as two critical markers of Group 3 MB, corresponding to its poor prognosis. Information on 33 clinical cases was further utilized for validation. Meanwhile, a global map of the molecular cascade downstream of the MYC oncogene in Group 3 MB was also delineated using single-cell RNA sequencing. Our data yields new insights into Group 3 MB molecular characteristics and provides novel therapeutic targets for this relentless disease.
Insights
Researchers identified novel molecular features in Group 3 medulloblastoma (MB), a highly malignant pediatric brain tumor. Key genes GRM8 and AP1S2 were found to be critical markers associated with poor prognosis in Group 3 MB.
Area of Science:
- Pediatric oncology
- Neuro-oncology
- Molecular biology
Background:
- Medulloblastoma (MB) is a highly heterogeneous and malignant pediatric brain tumor.
- Group 3 MB exhibits the worst prognosis among all MB subgroups.
- Molecular mechanisms driving Group 3 MB malignancy remain poorly understood.
Purpose of the Study:
- To identify novel molecular features of Group 3 MB.
- To understand the mechanisms maintaining malignancy in Group 3 MB.
- To discover potential therapeutic targets for Group 3 MB.
Main Methods:
- High-throughput single-cell and bulk RNA sequencing.
- Identification and validation of gene markers.
- Analysis of MYC oncogene downstream molecular cascade.
Main Results:
- A specific cell cluster with a highly malignant phenotype was identified in Group 3 MB.
- Glutamate receptor metabotropic 8 (GRM8) and AP-1 complex subunit sigma-2 (AP1S2) were identified as critical markers for Group 3 MB.
- Clinical data from 33 cases validated the identified markers.
- A molecular map of MYC oncogene downstream effects in Group 3 MB was delineated.
Conclusions:
- This study provides new insights into the molecular characteristics of Group 3 MB.
- GRM8 and AP1S2 represent novel therapeutic targets for Group 3 MB.
- Understanding these molecular features may improve treatment strategies for this aggressive pediatric brain tumor.
